Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps

2020 ◽  
Author(s):  
Nadia Suray Tan ◽  
Yew Kwang Ong ◽  
Manali Mukherjee ◽  
Siew Shuen Chao ◽  
W.S. Daniel Tan ◽  
...  
Keyword(s):  
Treatment Response ◽  
Nasal Polyps ◽  
Differential Treatment ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma

scholarly journals Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

2019 ◽  
Vol 159 ◽  
pp. 105806 ◽  
Author(s):  
Frank C. Albers ◽  
Christopher Licskai ◽  
Pascal Chanez ◽  
Daniel J. Bratton ◽  
Eric S. Bradford ◽  
...  
Keyword(s):  
Treatment Response ◽  
Eosinophil Count ◽  
Blood Eosinophil ◽  
Eosinophilic Asthma ◽  
Blood Eosinophil Count ◽  
Severe Eosinophilic Asthma

Benralizumab effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicentre Study

2021 ◽  
Author(s):  
Santi Nolasco ◽  
Claudia Crimi ◽  
Corrado Pelaia ◽  
Alida Benfante ◽  
Maria Filomena Caiaffa ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Chronic Rhinosinusitis ◽  
Real World ◽  
Nasal Polyps ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma

scholarly journals Efficacy Of Mepolizumab In Patients With Severe Eosinophilic Asthma And Nasal Polyps

2017 ◽  
Vol 139 (2) ◽  
pp. AB8 ◽  
Author(s):  
Mark C. Liu ◽  
Oliver N. Keene ◽  
Steven W. Yancey ◽  
Daniel J. Bratton ◽  
Frank C. Albers
Keyword(s):  
Nasal Polyps ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma

scholarly journals Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

Allergy ◽  
2016 ◽  
Vol 71 (9) ◽  
pp. 1335-1344 ◽  
Author(s):  
A. Magnan ◽  
A. Bourdin ◽  
C. M. Prazma ◽  
F. C. Albers ◽  
R. G. Price ◽  
...  
Keyword(s):  
Treatment Response ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma ◽  
Asthma Patients

Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma

2015 ◽  
Vol 136 (3) ◽  
pp. 825-826 ◽  
Author(s):  
Hector Ortega ◽  
Lynn Katz ◽  
Necdet Gunsoy ◽  
Oliver Keene ◽  
Steven Yancey
Keyword(s):  
Treatment Response ◽  
Blood Eosinophil ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma ◽  
Predict Treatment Response ◽  
Eosinophil Counts

scholarly journals Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Nora Drick ◽  
Benjamin Seeliger ◽  
Tobias Welte ◽  
Jan Fuge ◽  
Hendrik Suhling
Keyword(s):  
Treatment Response ◽  
Clinical Efficacy ◽  
Eosinophilic Asthma ◽  
Severe Eosinophilic Asthma

scholarly journals Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbidities

2020 ◽  
Author(s):  
Claudia Crimi ◽  
Raffaele Campisi ◽  
Giulia Cacopardo ◽  
Rossella Intravaia ◽  
Santi Nolasco ◽  
...  
Keyword(s):  
Treatment Response ◽  
Real Life ◽  
Forced Expiratory Volume ◽  
Blood Eosinophil ◽  
Asthma Control Test ◽  
Eosinophilic Asthma ◽  
Life Effectiveness ◽  
Blood Eosinophil Count ◽  
Severe Eosinophilic Asthma ◽  
Act Score

AbstractBACKGROUNDPatients with severe asthma often suffer from comorbidities whose impact on the course of biological therapy has not been elucidated yet.OBJECTIVETo evaluate real-life effectiveness and the presence/absence of predictors of treatment response in patients with one or more comorbidities who received mepolizumab (MEPO) for the treatment of severe eosinophilic asthma (EA).METHODSHealth records of 31 patients were retrospectively analyzed. Asthma control test (ACT) score, blood eosinophil count, forced expiratory volume in 1 second (FEV1), FEV1% of predicted and FEV1/FVC (Forced Vital Capacity) ratio, oral corticosteroid (OCS) dosage and exacerbations were recorded at baseline (T0), after 3 (T1), 6 (T3), nine (T6) and 12 months (T12). A clinical response was defined as: i) 30% exacerbation decrease; ii) 80% blood eosinophilia reduction; iii) 3 point ACT increase; iv) FEV1 increase ≥ 200 mL.RESULTSAt T12 blood eosinophil level decreased by 89.89% (p>0.0001), an improvement in ACT of 3 points from baseline was recorded in 80.65% of patients (p>0.0001) and 96.77% of patients reduced by minimum 30% the number of exacerbations (p>0.0001). 84% of patients discontinued OCS (p>0.0001). FEV1 increased by 0.22 (p=0.0224) while FEV1/FVC was statistically significant only at T1. No significant differences were generally found among patients with a specific comorbidity. The number of comorbidities did not influence treatment response. Neither the comorbidities nor other characteristics (sex, BMI, age, smoking, baseline eosinophil level) influenced treatment response.CONCLUSIONSMEPO in patients with severe EA is effective regardless of the presence of one or more comorbidities.

Sign in / Sign up

Export Citation Format

Share Document